Palantir: 93% Growth Beats The Wall, But At $301 Billion There Is No Margin For Error

Palantir Technologies (NASDAQ: PLTR) delivered another blowout quarter. Revenue jumped 93% year-over-year to $1.94 billion. Adjusted earnings per share of $0.41 beat consensus of $0.34. U.S. commercial revenue - the growth engine the bulls need - accelerated to 149% year-over-year. Management raised full-year guidance to $8.15–$8.16 billion, well above the $7.72 billion consensus, and projected Q3 revenue of $2.16–$2.164 billion, ahead of the $2.00 billion Street estimate.

The numbers are undeniable. The question they force is the one Palantir's current price refuses to answer: at a $301 billion market cap, how much more has to happen for this stock to make sense?

The operating case is strong - and getting stronger

Palantir's Q2 results are not incremental. They are the kind of numbers that reset the growth curve. Revenue climbed from roughly $1 billion a year ago to $1.94 billion, marking the company's highest growth rate ever. The U.S. business, which now comprises over 81% of total revenue, grew 115% year-over-year and 23% sequentially. Commercial was the star, surging 149% to $764 million, while government revenue grew 90% to $809 million.

Profitability is equally striking. GAAP operating margin hit 47%, or $912 million on the quarter. Adjusted operating income reached $1.19 billion for a 62% margin. Adjusted free cash flow - operating cash flow minus capital expenditures, a rough measure of actual cash the business generates - came in at $1.22 billion, or 63% of revenue. Palantir closed 220 deals worth $1 million or more, including 73 contracts above $10 million. Remaining U.S. commercial deal value more than doubled year-over-year to $6.24 billion.

The full-year guidance raise reinforces the acceleration theme. Management now expects revenue growth of roughly 82% for the full year, with U.S. commercial revenue exceeding $3.42 billion - at least 134% annual growth. Adjusted operating income guidance sits at $4.89–$4.90 billion and adjusted free cash flow at $4.5–$4.7 billion.

CEO Alex Karp told CNBC after the report that this growth trajectory "looks like this is going to go on for at least another 18 months." He also used the moment to widen his attack on OpenAI and Anthropic's token-based pricing model, calling it "completely wrong" and arguing enterprises are frustrated by skyrocketing costs and the risk of giving away their competitive secrets. Palantir, he says, lets companies own their data, models, and compute.

The valuation problem is separate from the business problem

Here is where the analyst who is "running out of superlatives" and the disciplined investor diverge. The business case is exceptional. The stock case is a different animal.

Palantir currently trades at roughly 100 times trailing GAAP earnings, 279 times forward earnings, and 49 times trailing sales. Enterprise value to EBITDA is 110x. Price-to-book is 30.5x. These are not "rich" multiples in the abstract - they are the kind of multiples that price in years of flawless execution, assume no competitive disruption, and require growth that almost no other software company at this scale has sustained.

To put that in context: Datadog, a faster-growing SaaS name by some measures, trades at 26.5x sales. CrowdStrike sits at 40.5x sales but has yet to produce positive GAAP earnings. Palantir at 49x sales needs to deliver something no peer has done - compound triple-digit revenue growth while expanding margins, and keep doing it, for years.

That is not impossible. It is simply already priced in. The stock is up roughly 56% over the past twelve months even after its 29% year-to-date decline from a 52-week high of $207.52. A post-earnings surge of 8-9% after these numbers tells you what sentiment is doing, not whether the math works from here.

The growth narrative check passes. Palantir is not one of those names where AI is a buzzword with no revenue behind it. The AIP platform, forward-deployed engineers, and customer-specific benchmarks are converting into $1.94 billion quarters, 220 seven-figure deals, and a 157% net dollar retention rate. The Karp-vs.-token-labs narrative may be self-serving - Fortune noted last month that there is little evidence frontier labs are literally "stealing alpha" from enterprise customers - but it aligns with a real market shift. Enterprises are wrestling with token costs, ROI uncertainty, and the desire to keep proprietary data in-house. Palantir is well-positioned to capture that demand.

But narrative alignment and revenue proof do not cure valuation risk. A 62% adjusted operating margin at 49x sales means the market is paying five times revenue for every dollar of top line, expecting that margin quality to persist while growth stays above 80% annually. If growth decelerates to 50%, even with expanding margins, the multiple compression risk is severe. If government spending on AI-enabled defense slows due to budget pressures, or if commercial demand softens as AI fatigue spreads through the enterprise, the thesis takes a hit without any change in business quality.

What would justify buying, and what would make me walk away

The stock that fell 29% year-to-date was the version that looked marginally more interesting - one where valuation had done some of the work for the buyer. At $125, after a post-earnings pop, the reset is mostly gone. The current price implies confidence that the 80%+ growth trajectory holds for the full year and beyond, that commercial adoption continues at 140%+ rates, and that competition from cloud providers, open-source alternatives, and the very frontier labs Karp criticizes does not erode margins or slow deal velocity.

A compelling entry for this stock requires either a deeper valuation reset or evidence that growth is transitioning from explosive to durable at a slightly slower pace - the kind of inflection that still supports earnings compounding but at a multiple that has room for one bad quarter. Until then, the operating story is a five-star business and the stock story is a one-dimensional bet.

Rating: Hold. Too expensive for what the next phase can reasonably support.

The catalyst clock points to Q3 earnings in early November, when the $2.16 billion revenue guidance and commercial trajectory will be tested against reality. If Palantir clears that bar and maintains its current run rate, the multiple may hold. But at these levels, the risk/reward is tilted toward downside. A 93% growth quarter is extraordinary. A stock that demands perfection from here on out is a different proposition entirely.